Lonza expands cell and gene therapy portfolio
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
Cagrilintide represents a novel approach to obesity management
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Subscribe To Our Newsletter & Stay Updated